Liraglutide is marketed in Europe as Victoza® (1.2 mg/1.8 mg), indicated for glycaemic control in type 2 diabetes, and Saxenda® (3.0 mg), indicated for weight management in adults with obesity. We performed a post-authorization safety study (PASS) to assess the in-market use of Saxenda® and Victoza® according to approved indications and posology.This retrospective, non-interventional study was conducted at 41 sites between December 2016 and May 2019. Via medical record review, physicians at each site identified patients who had been prescribed Saxenda® (Italy) or Victoza® (Italy/Germany) within the 24 months following launch in each country. Pseudonymized data were abstracted on patient and site characteristics, indication for the prescription, posology and duration of usage. Adherence to the approved indications and posology, and to the Saxenda® stopping rule, were assessed. No formal statistical analysis was performed.A total of 440 patients were pre-screened and 225 (51.1%) were enrolled (Saxenda®: N=75, all in Italy; Victoza®: N=75 in Italy; N=75 in Germany). In all, 96% (72/75) of Saxenda® prescriptions, and 98.7% (148/150) of Victoza®, were in accordance with the approved indications. Among the 40 patients treated with Saxenda® for ≥16 weeks, only two (5.0%) were confirmed as non-adherent to the stopping rule. Adherence could not be assessed in 23 (57.5%) patients owing to missing body weight measurements.This retrospective, real-world PASS provides reassurance that Saxenda® and Victoza® are primarily used according to the approved European label, thus their real-world utilization does not raise safety concerns.gov identifier: NCT02967757. This article is protected by copyright. All rights reserved.